Can radiation-recall predict long lasting response to immune checkpoint inhibitors?
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 32976876.
- Also identified by DOI 10.1016/j.radonc.2020.09.037.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
RR secondary to ICI (nivolumab in all patients) were observed in the lung (n = 1) or skin (n = 3). All patients had a long-term response to ICI and are currently alive with no active disease (Median FU from ICI discontinuation: 30 months). RR could reflect a beneficial immune activation and constitute a predictive clinical biomarker of ICI long-term efficacy.
Medical subject headings
- Immune Checkpoint Inhibitors
- Nivolumab